Impact assessment of a decision rule for using antibiotics in pneumonia: a randomized trial

Fernando A Torres1, Irma Pasarelli, Adrián Cutri

  • 1Departamento de Consultorios Externos, Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina.

Pediatric Pulmonology
|September 17, 2013
PubMed

Insights

The bacterial pneumonia score (BPS) significantly reduced antibiotic use in children with pneumonia. This approach did not increase the risk of treatment failure, offering a safer management strategy.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Most childhood pneumonia cases are viral, yet antibiotics are frequently prescribed.
  • The bacterial pneumonia score (BPS) aids in identifying children who don't need antibiotics.
  • The clinical impact of using BPS for pneumonia management in children was previously unevaluated.

Purpose of the Study:

  • To evaluate if using the bacterial pneumonia score (BPS) for initial management of childhood pneumonia reduces antibiotic prescriptions.
  • To determine if BPS-guided management increases patient risks compared to standard care.

Main Methods:

  • A randomized, parallel-group, observer-blind, controlled trial was conducted.
  • Children aged 3-60 months with pneumonia were assigned to BPS-guided management (BPS ≥ 4) or routine management.
  • Antibiotic use proportions and clinical outcomes were compared between groups.

Main Results:

  • Antibiotic use was significantly lower in the BPS group (46.6%) compared to the routine management group (86.6%).
  • No significant difference in unfavorable outcomes was observed between the BPS group and the control group (8.3% overall).

Conclusions:

  • Management guided by the bacterial pneumonia score (BPS) significantly decreases antibiotic use in children with pneumonia.
  • BPS-guided management is effective and does not elevate the rate of treatment failure.
Abstract

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...